$1,720,000 of PFIZER INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign Freeriding Issues Non-Tariff Trade Barriers Trade Issues"
You can find more data on corporate lobbying on Quiver Quantitative.
PFE Congressional Stock Trading
Members of Congress have traded $PFE stock 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $PFE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 1 purchase worth up to $15,000 on 11/18 and 2 sales worth up to $30,000 on 12/19, 08/05.
- REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 08/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
PFE Hedge Fund Activity
We have seen 1,274 institutional investors add shares of PFE stock to their portfolio, and 1,378 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 24,513,278 shares (+55.9%) to their portfolio in Q3 2025, for an estimated $624,598,323
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 17,885,662 shares (-23.7%) from their portfolio in Q3 2025, for an estimated $455,726,667
- WELLINGTON MANAGEMENT GROUP LLP removed 16,541,586 shares (-21.5%) from their portfolio in Q3 2025, for an estimated $421,479,611
- MILLENNIUM MANAGEMENT LLC removed 12,237,392 shares (-87.4%) from their portfolio in Q3 2025, for an estimated $311,808,748
- BNP PARIBAS FINANCIAL MARKETS removed 11,413,258 shares (-54.2%) from their portfolio in Q3 2025, for an estimated $290,809,813
- ROYAL BANK OF CANADA added 9,722,744 shares (+33.0%) to their portfolio in Q3 2025, for an estimated $247,735,517
- THORNBURG INVESTMENT MANAGEMENT INC removed 9,009,301 shares (-86.1%) from their portfolio in Q3 2025, for an estimated $229,556,989
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PFE Analyst Ratings
Wall Street analysts have issued reports on $PFE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/24/2025
To track analyst ratings and price targets for PFE, check out Quiver Quantitative's $PFE forecast page.
PFE Price Targets
Multiple analysts have issued price targets for $PFE recently. We have seen 7 analysts offer price targets for $PFE in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Michael Yee from UBS set a target price of $25.0 on 01/07/2026
- Terence Flynn from Morgan Stanley set a target price of $27.0 on 12/17/2025
- Jason Gerberry from B of A Securities set a target price of $28.0 on 12/15/2025
- Geoff Meacham from Citigroup set a target price of $26.0 on 12/02/2025
- Vamil Divan from Guggenheim set a target price of $35.0 on 11/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
